Nonetheless, a very recent study (2022) proposes prostate-specific membrane antigen (PSMA) as a promising future therapeutic target against PCa, as it demonstrates that this protein modulates PCa progression by regulating arginine and L-proline biosynthesis (its depletion promoted the synthesis of these two AA and inhibited androgen receptor expression) [26]. Here, FOLH1 is linked to posterior cortical atrophy.